Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Smyth MJ, Teng MW. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med. 2016;8:111.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835–2840.
   PubMed Web of Science ®Google Scholar
• Hassel JC, Heinzerling L, Aberle J, Bahr O, Eigentler TK, Grimm MO, Grunwald V, Leipe J, Reinmuth N, Tietze JK, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36:477–489. doi:10.1097/01.cji.0000436722.46675.4a.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16. doi:10.1186/s40425-017-0218-5.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–584. doi:10.1038/nrd4591.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12:303–312. doi:10.1016/j.ccr.2007.10.001.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066–1075. doi:10.1038/sj.cdd.4400943.
   PubMed Web of Science ®Google Scholar
• Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72. doi:10.1016/j.ceb.2017.11.005.
   PubMed Web of Science ®Google Scholar
• Valente JF, Queiroz JA, Sousa F. p53 as the focus of gene therapy: past, present and future. Curr Drug Targets. 2018;19. doi:10.2174/1389450119666180115165447.
   PubMed Web of Science ®Google Scholar
• Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell. 2012;21:614–625. doi:10.1016/j.ccr.2012.03.042.
   PubMed Web of Science ®Google Scholar
• Menendez D, Shatz M, Resnick MA. Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol. 2013;25:85–92. doi:10.1097/CCO.0b013e32835b6386.
   PubMed Web of Science ®Google Scholar
• Cui Y, Guo G. Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment. Int J Mol Sci. 2016;17:E1942. doi:10.3390/ijms17111942.
   Web of Science ®Google Scholar
• Kim SS, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther. 2014;22:278–291. doi:10.1038/mt.2013.231.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403–416. doi:10.18632/oncotarget.v5i2.
   PubMed Web of Science ®Google Scholar
• Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene. 1999;18:7740–7747. doi:10.1038/sj.onc.1203235.
   PubMed Web of Science ®Google Scholar
• Moore EC, Sun L, Clavijo PE, Friedman J, Harford JB, Saleh AD, Van Waes C, Chang EH, Allen CT. Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. OncoImmunology. 2018;7:e1404216. doi:10.1080/2162402X.2017.1404216.
   PubMed Web of Science ®Google Scholar
• Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CS, Chen M, Monjazeb AM, Kelly K, Blazar BR, et al. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 2016;5:e1075114. doi:10.1080/2162402X.2015.1075114.
   PubMed Web of Science ®Google Scholar
• McGuire HM, Shklovskaya E, Edwards J, Trevillian PR, McCaughan GW, Bertolino P, McKenzie C, Gourlay R, Gallagher SJ, Fazekas de St Groth B, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother. 2018;67:563–573. doi:10.1007/s00262-017-2107-7
   PubMed Web of Science ®Google Scholar
• Kudlak K, Demuro JP, Hanna AF, Brem H. Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor. Int J Crit Illn Inj Sci. 2013;3:279–281. doi:10.4103/2229-5151.124168.
   PubMedGoogle Scholar
• Descotes J. Immunotoxicity of monoclonal antibodies. MAbs. 2009;1:104–111. doi:10.4161/mabs.1.2.7909.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22:7486–7495. doi:10.1038/sj.onc.1206949.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, Pirollo KF, Nishida M, Farkas N, Dagata JA, Chang EH. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8:5494–5514. doi:10.1021/nn5014484.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, Pirollo KF, Chang EH. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine. 2015;11:301–311. doi:10.1016/j.nano.2014.09.005.
   PubMed Web of Science ®Google Scholar
• Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10:2941–2952. doi:10.1089/10430349950016357.
   PubMed Web of Science ®Google Scholar
• Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol. 2016;16:741–750. doi:10.1038/nri.2016.99.
   PubMed Web of Science ®Google Scholar
• Guo G, Yu M, Xiao W, Celis E, Cui Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 2017;77:2292–2305. doi:10.1158/0008-5472.CAN-16-2832.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343–354. doi:10.1016/j.immuni.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol. 2012;2:191. doi:10.3389/fonc.2012.00191.
   PubMedGoogle Scholar
• Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, Liu P, Yang H, Bezu L, Müller K, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016;7:e2134. doi:10.1038/cddis.2016.47.
   PubMed Web of Science ®Google Scholar
• Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77:839–850. doi:10.1158/0008-5472.CAN-15-3142.
   PubMed Web of Science ®Google Scholar
• Lettau M, Paulsen M, Schmidt H, Janssen O. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2011;90:456–466. doi:10.1016/j.ejcb.2010.10.006.
   PubMed Web of Science ®Google Scholar
• Braun MW, Iwakuma T. Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res. 2016;5:692–697. doi:10.21037/tcr.
   PubMed Web of Science ®Google Scholar
• Wang B, Niu D, Lai L, Ren EC. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun. 2013;4:2359. doi:10.1038/ncomms3359.
   PubMed Web of Science ®Google Scholar
• Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, Mami-Chouaib F, Chouaib S. p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol. 2005;174:871–878. doi:10.4049/jimmunol.174.2.871.
   PubMed Web of Science ®Google Scholar
• Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;15:3032–3040. doi:10.1128/MCB.15.6.3032.
   PubMed Web of Science ®Google Scholar
• Meslin F, Thiery J, Richon C, Jalil A, Chouaib S. Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells. J Biol Chem. 2007;282:32991–32999. doi:10.1074/jbc.M705290200.
   PubMed Web of Science ®Google Scholar
• Ben Safta T, Ziani L, Favre L, Lamendour L, Gros G, Mami-Chouaib F, Martinvalet D, Chouaib S, Thiery J. Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol. 2015;194:418–428. doi:10.4049/jimmunol.1401978.
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Gi M, Yamano S, Tachibana H, Okuno T, Tamada S, Nakatani T, Wanibuchi H. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci. 2016;107:1736–1744. doi:10.1111/cas.2016.107.issue-12.
   PubMed Web of Science ®Google Scholar
• Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6:40836–40849. doi:10.18632/oncotarget.5696.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13:412–424. doi:10.1016/j.celrep.2015.08.077.
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 INHIBITORS: from bench to bedside. Cancer Res. 2017;77:6795–6811. doi:10.1158/0008-5472.CAN-17-2285.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829. doi:10.1056/NEJMoa1604958.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–5074. doi:10.1158/1078-0432.CCR-13-3271.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102–4109. doi:10.1200/JCO.2016.67.2477.
   PubMed Web of Science ®Google Scholar
• Jing W, Li M, Zhang Y, Teng F, Han A, Kong L, Zhu H. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther. 2016;9:489–502. doi:10.2147/OTT.S94993.
   PubMed Web of Science ®Google Scholar
• Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11:91–99. doi:10.1038/nrclinonc.2013.245.
   PubMed Web of Science ®Google Scholar
• Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo KF, Rait A, Chang EH. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013;21:1096–1103. doi:10.1038/mt.2013.32.
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Nemunaitis J, Leung PK, Nunan R, Adams J, Chang EH. Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study. Mol Ther. 2016;24:1697–1706. doi:10.1038/mt.2016.135.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–346.
   PubMed Web of Science ®Google Scholar
• Yu W, Pirollo KF, Yu B, Rait A, Xiang L, Huang W, Zhou Q, Ertem G, Chang EH. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res. 2004;32:e48. doi:10.1093/nar/gnh049.
   PubMed Web of Science ®Google Scholar
• Bresler SC, Min L, Rodig SJ, Walls AC, Xu S, Geng S, Hodi FS, Murphy GF, Lian CG. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Lab Invest. 2017;97:207–216. doi:10.1038/labinvest.2016.126.
   PubMed Web of Science ®Google Scholar